Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Pelthos Q2 2026: Zelsuvmi growth accelerates; financing secured; 2027 launches ahead

Aug 13, 2026, 7:14 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Zelsuvmi demand trajectory improves near-term revenue visibility; balance sheet liquidity via Horizon facility reduces funding risk; planned 2027 launches add optionality. However, ongoing losses and cash burn temper upside until profitability or milestone revenues materialize.

AI summary

What happened, with direct paths to the underlying reporting

Pelthos reported Q2 2026 results with Zelsuvmi sales accelerating, generating $15.4 million in net product revenue and marking a 45% QoQ increase. The company secured a $50 million Horizon loan facility, drawing $30 million and signaling optional access to an additional $10 million, while maintaining a $24.2 million cash balance. Management outlined planned launches of Xepi in 2027 and Xeglyze in 2027, which could broaden revenue opportunities if adopted alongside growing Zelsuvmi uptake.

Zelsuvmi Q2 2026 net product revenue $15.4m, +45% QoQ from $10.7m.
Q2 dispensed units 11,925; 4,571 prescribers; 29,126 units dispensed to 7,414 prescribers total.
Horizon loan facility: $50m; drawn $30m; potential additional $10m; cash $24.2m.
Xepi (Q1 2027) and Xeglyze (Q3 2027) commercialization planned; capital plan outlined.
Net loss $23.4m; Adjusted EBITDA -$5.7m; ongoing cash burn with growth trajectory.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.